New eye drops could replace reading glasses for presbyopia
NCT ID NCT05728944
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tested LNZ101 eye drops in 229 people aged 45-75 with presbyopia, a condition that makes it hard to see up close. The drops combine aceclidine and brimonidine to temporarily improve near vision. The main goal was to see if participants could read three lines better on an eye chart without losing distance vision. The study is complete, offering hope for a non-surgical option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aceclidine and brimonidine combination eye drops
What this could lead to
If it works, this could offer a non-surgical, temporary fix for reading vision in people with presbyopia.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to everyone. The effect is temporary and requires repeated use. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EYE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site #203
Newport Beach, California, 92663, United States
-
Site #204
Danbury, Connecticut, 06810, United States
-
Site #205
Crystal River, Florida, 34429, United States
-
Site #207
Powell, Ohio, 43065, United States
-
Site #208
St Louis, Missouri, 63128, United States
-
Site #209
Dothan, Alabama, 36301, United States
-
Site #211
Louisville, Kentucky, 40206, United States
-
Site #212
West Fargo, North Dakota, 58078, United States
-
Site #213
Eugene, Oregon, 97401, United States
-
Site #214
La Jolla, California, 92037, United States
-
Site #215
Bozeman, Montana, 59718, United States
-
Site #216
Scottsdale, Arizona, 85260, United States
-
Site #217
Warwick, Rhode Island, 02888, United States
-
Site #218
Northbrook, Illinois, 60062, United States
-
Site #219
Dover, New Jersey, 07801, United States
-
Site #220
Glendale, California, 91204, United States
-
Site #221
Rochester, New York, 14626, United States